# Oral Lung-Disease Tablets Insmed Brings BRINSUPRI to Japan for NCFB By Amy Duong | Written with AI assistance | Published 2026-10-20 | Business Source: Trend Hunter, https://www.trendhunter.com/trends/oral-lung-disease-tablets References: [prnewswire](https://www.prnewswire.com/news-releases/insmed-launches-brinsupri-tablets-25-mg-brensocatib-hydrate-for-the-treatment-of-non-cystic-fibrosis-bronchiectasis-in-japan-302911560.html)  Insmed brought BRINSUPRI Tablets 25 mg to Japan, giving adults and pediatric patients 12 years and older an [oral once-daily option](https://www.trendhunter.com/trends/brain-cancer-treatment) for non-cystic fibrosis bronchiectasis. The brensocatib hydrate tablet is designed to act on the inflammatory process tied to the disease, rather than only chasing symptoms after flare-ups begin. In Japan, BRINSUPRI is available by prescription, and the 25 mg strength keeps the dose clear and simple for a chronic condition that needs regular treatment. The tablet format also fits a daily routine more naturally than therapies that depend on [repeated clinic visits](https://www.trendhunter.com/trends/avenacy-1). At [prescription-only availability in Japan](https://www.trendhunter.com/trends/ct), BRINSUPRI becomes the first and only approved commercial treatment for this patient group there. That position can shift bronchiectasis care from symptom management toward a more direct, disease-specific option. Image Credit: Insmed Incorporated ## Trend Insights (Trend Hunter) - Score: 5.0/10 - Popularity: 18% | Activity: 34% | Freshness: 99% - Audience gender: 50% men, 50% women - Primary generations: Gen Z - Top markets: Asia ## Categories [Trend Hunter](https://www.trendhunter.com/trends) > [Business](https://www.trendhunter.com/business) > [New Ventures](https://www.trendhunter.com/newventures) ## Key Themes ### Why This Trend Is Growing - **Once-daily Respiratory Tablets:** Oral dosing formats are reshaping chronic lung-disease care by reducing dependence on clinic-based therapies and supporting easier long-term adherence. - **Disease-modifying Bronchiectasis Care:** Targeting underlying inflammatory pathways creates room for differentiated respiratory treatments that move beyond reactive flare-up management. - **Pediatric-adult Chronic Therapies:** Medicines approved across adolescent and adult populations can simplify care continuity and expand addressable markets for chronic disease platforms. ### Industries Being Reshaped - **Respiratory Pharmaceuticals:** First-in-class therapies for underserved lung conditions signal premium market potential in disease-specific respiratory drug development. - **Specialty Prescription Medicine:** Prescription-only launches for narrow patient groups highlight the growing value of targeted commercial strategies in chronic specialty care. - **Japanese Healthcare:** Japan’s approval of novel chronic respiratory treatments reflects opportunities for global biopharma firms to localize breakthrough therapies for regulated regional markets. ## Related on Trend Hunter - [Daily Lung Health Systems](https://www.trendhunter.com/trends/respiratory-care.md) - [Dog-Specific Muscle Injections](https://www.trendhunter.com/trends/Biotech-Firm-Snoretox.md) - [Needle-Free Peptide Therapies](https://www.trendhunter.com/trends/needle-free-peptide-therapies.md) - [Pediatric Arthritis Treatments](https://www.trendhunter.com/trends/rinvoq-oral-solution.md) - [Eu-Wide Biosimilar Drug Expansions](https://www.trendhunter.com/trends/biosimilar-drug.md) - [Targeted Rare Disease Therapies](https://www.trendhunter.com/trends/reduces-new-bone-growth.md) - [Generic Pulmonary Hypertension Drugs](https://www.trendhunter.com/trends/generic-pulmonary-hypertension-tablets.md) - [Portable Respiratory Care Devices](https://www.trendhunter.com/trends/portable-respiratory-care-devices.md) - [Short-Acting Cancer Biosimilars](https://www.trendhunter.com/trends/short-acting-cancer-biosimilars.md)